We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Bisphosphonate-related osteonecrosis of the jaw (BRONJ) associated with a once-yearly IV infusion of zoledronic acid (Reclast) 5 mg: Two cases and review of the literature.
- Authors
Katz, Joseph; Ordoveza, Patrisha A.
- Abstract
The use of a once-yearly IV infusion of 5 mg zoledronic acid has become more common, as the drug is being reported as safe, with few to minimal adverse reactions. This one-time annual administration has a favorable outcome for patients with osteoporosis and spares the burden of taking daily oral bisphosphonates. The present literature search found 10 well-documented cases of bisphosphonate-related osteonecrosis of the jaw (BRONJ) associated with annual administration of 5 mg zoledronic acid for the treatment of osteoporosis. Two new cases are also described, with underlying risk factors similar to previous reports. These include prior dental surgical procedures, the presence of diabetes, autoimmune conditions, past use of bisphosphonate and steroids, and concomitant immunosuppression. Although the reported incidence of BRONJ related to once-a-year IV administered zoledronic acid is low, it may be plausible. Both medical and dental clinicians should be aware of its manifestation.
- Subjects
OSTEONECROSIS; DIPHOSPHONATES; INTRAVENOUS therapy; JAWS; ZOLEDRONIC acid
- Publication
Quintessence International, 2014, Vol 45, Issue 8, p685
- ISSN
0033-6572
- Publication type
Article
- DOI
10.3290/j.qi.a32242